interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Testosterone Undecanoate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Testosterone Undecanoate, and who makes it?

Testosterone Undecanoate appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Testosterone Undecanoate2 dosage-form groups in the Orange Book
0generic makers listed
  1. Testosterone Undecanoate appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Capsule, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Jatenzo, Kyzatrex and Tlando. No generic is listed as marketed.

201520202025203020352040204501brand 2019data datePatent 11331325 listed to expire 6 January 2027Patent 11304960 listed to expire 8 January 2029Patent 8865695 listed to expire 8 January 2029Patent 8778922 listed to expire 8 January 2029Patent 8241664 listed to expire 29 March 2029Patent 10543219 listed to expire 12 April 2030Patent 11179403 listed to expire 12 April 2030Patent 11426416 listed to expire 12 April 2030Patent 10617696 listed to expire 12 April 2030Patent 8778916 listed to expire 12 April 2030Patent 11433083 listed to expire 30 November 2030Patent 11364249 listed to expire 30 November 2030Patent 10716794 listed to expire 30 November 2030Patent 9949985 listed to expire 30 November 2030Patent 11311555 listed to expire 30 November 2030Patent 10226473 listed to expire 30 November 2030Patent 9943527 listed to expire 30 November 2030Patent 8492369 listed to expire 20 December 2030Patent 10576089 listed to expire 31 December 2030Patent 11590146 listed to expire 31 December 2030Patent 10576090 listed to expire 31 December 2030Patent 11617758 listed to expire 15 March 2033Patent 12357643 listed to expire 15 March 2033Patent 11559530 listed to expire 28 November 2037Patent 12310978 listed to expire 21 February 2039Patent 11564933 listed to expire 12 April 2039Patent 12605391 listed to expire 12 April 2039Patent 12011503 listed to expire 16 October 2040Patent 12403146 listed to expire 29 March 2041Patent 11464735 listed to expire 28 April 2041Patent 12691057 listed to expire 28 April 2041
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 6 January 2027Patent 11331325
  • 8 January 2029Patent 11304960 drug product
  • 8 January 2029Patent 8865695
  • 8 January 2029Patent 8778922 drug product
  • 29 March 2029Patent 8241664 drug product
  • 12 April 2030Patent 10543219
  • 12 April 2030Patent 11179403
  • 12 April 2030Patent 11426416

23 more patents are listed.

Injectable, Intramuscular

Brand listed, no generic listed as marketed

Brand listed as marketed: Aveed. No generic is listed as marketed.

2010201520202025203001brand 2014data datePatent 7718640 listed to expire 14 March 2027Patent 8338395 listed to expire 8 May 2027
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 14 March 2027Patent 7718640 drug product
  • 8 May 2027Patent 8338395

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.